Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

25-Hydroxyvitamin D depletion does not exacerbate MPTP-induced dopamine neuron damage in mice.

Dean ED, Mexas LM, Cápiro NL, McKeon JE, DeLong MR, Pennell KD, Doorn JA, Tangpricha V, Miller GW, Evatt ML.

PLoS One. 2012;7(7):e39227. doi: 10.1371/journal.pone.0039227. Epub 2012 Jul 2.

2.

The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.

Ding YX, Xia Y, Jiao XY, Duan L, Yu J, Wang X, Chen LW.

Neurochem Res. 2011 Oct;36(10):1759-66. doi: 10.1007/s11064-011-0491-5. Epub 2011 May 12.

PMID:
21562748
3.

The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.

Drouin-Ouellet J, Gibrat C, Bousquet M, Calon F, Kriz J, Cicchetti F.

J Neuroinflammation. 2011 Oct 11;8:137. doi: 10.1186/1742-2094-8-137.

4.

Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.

Vivacqua G, Biagioni F, Yu S, Casini A, Bucci D, D'Este L, Fornai F.

J Chem Neuroanat. 2012 Jul;44(2):76-85. doi: 10.1016/j.jchemneu.2012.04.003. Epub 2012 May 8.

PMID:
22580273
5.
6.

Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.

Depboylu C, Rösler TW, de Andrade A, Oertel WH, Höglinger GU.

J Neurochem. 2015 May;133(4):590-7. doi: 10.1111/jnc.13026. Epub 2015 Jan 26.

7.

Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.

Zhang L, Huang L, Chen L, Hao D, Chen J.

Toxicol Lett. 2013 Oct 24;222(2):155-63. doi: 10.1016/j.toxlet.2013.07.020. Epub 2013 Aug 1.

PMID:
23911879
8.
9.

Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice.

Wang Q, Shin EJ, Nguyen XK, Li Q, Bach JH, Bing G, Kim WK, Kim HC, Hong JS.

J Neuroinflammation. 2012 Jun 13;9:124. doi: 10.1186/1742-2094-9-124.

10.

Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.

Choi DY, Lee MK, Hong JT.

Neurobiol Dis. 2013 Jan;49:159-68. doi: 10.1016/j.nbd.2012.08.001. Epub 2012 Aug 10.

PMID:
22922220
11.

Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.

Kim HW, Choi WS, Sorscher N, Park HJ, Tronche F, Palmiter RD, Xia Z.

Neurobiol Aging. 2015 Sep;36(9):2617-27. doi: 10.1016/j.neurobiolaging.2015.05.008. Epub 2015 May 16.

12.

The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.

Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T.

Neuropharmacology. 2015 Oct;97:86-94. doi: 10.1016/j.neuropharm.2015.05.015. Epub 2015 May 23.

PMID:
26006269
13.

Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.

Breckenridge CB, Sturgess NC, Butt M, Wolf JC, Zadory D, Beck M, Mathews JM, Tisdel MO, Minnema D, Travis KZ, Cook AR, Botham PA, Smith LL.

Neurotoxicology. 2013 Jul;37:1-14. doi: 10.1016/j.neuro.2013.03.005. Epub 2013 Mar 21.

14.

Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.

Kuhlmann AC, Guilarte TR.

Toxicol Sci. 1999 Mar;48(1):107-16.

PMID:
10330690
15.

Neuroprotection in Parkinson models varies with toxin administration protocol.

Anderson DW, Bradbury KA, Schneider JS.

Eur J Neurosci. 2006 Dec;24(11):3174-82.

PMID:
17156378
16.

14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Ding H, Underwood R, Lavalley N, Yacoubian TA.

Neuroscience. 2015 Oct 29;307:73-82. doi: 10.1016/j.neuroscience.2015.08.042. Epub 2015 Aug 24.

18.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
19.

Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Yasuda Y, Shinagawa R, Yamada M, Mori T, Tateishi N, Fujita S.

Brain Res. 2007 Mar 23;1138:196-202. Epub 2006 Dec 23.

PMID:
17275793
20.

Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.

Franke SK, van Kesteren RE, Wubben JA, Hofman S, Paliukhovich I, van der Schors RC, van Nierop P, Smit AB, Philippens IH.

Neuroscience. 2016 Jan 15;312:247-59. doi: 10.1016/j.neuroscience.2015.09.065. Epub 2015 Oct 9.

PMID:
26431624

Supplemental Content

Support Center